DB
KRYS icon

Danske Bank’s Krystal Biotech KRYS Stock Holding History

Danske Bank’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$49.3K – 1381
2025
Q4 		$49.3K Hold
200
– – ﹤0.01% 999
2025
Q3 		$35.3K Hold
200
– – ﹤0.01% 1085
2025
Q2 		$27.5K Buy
+200
New +$29.4K ﹤0.01% 1129
2024
Q4 		– Sell
-300
Closed -$54.6K – 1535
2024
Q3 		$54.6K Buy
+300
New +$57.8K ﹤0.01% 1175

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Danske Bank's KRYS Position: Q1 2026 in Review

Danske Bank sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 200 shares — an estimated $49.3K sold.

Danske Bank first reported a position in KRYS in Q3 2024 and held it in 4 quarters. The position peaked at $54.6K in Q3 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Danske Bank reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Danske Bank sold 200 Krystal Biotech shares in Q1 2026, an estimated $49.3K.
  • Danske Bank first reported a position in Krystal Biotech in Q3 2024 and held it in 4 quarters.
  • Danske Bank's Krystal Biotech position peaked at $54.6K in Q3 2024.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.